Repotrectinib Sustains ORR, Safety in Locally Advanced or Me

Treatment with repotrectinib continued to produce high and durable responses with a manageable safety profile in patients with ROS1-positive locally advanced or metastatic non–small cell lung cancer who were naïve to a TKI or previously treated with 1 TKI and no chemotherapy.

Related Keywords

South Korea , Seoul , Soult Ukpyolsi , Joseph Fiore , Byoung Chul Cho , Cancer Laboratory , Drug Administration , Yonsei Cancer Center , Bristol Myers Squibb , Yonsei University College Of Medicine , Lung Cancer , Chul Cho , Yonsei University College , Prescription Drug User Fee , Point Therapeutics , Patients With Advanced Solid Tumors , Repotrectinib , Nsclc , Trident 1 ,